Vivos Therapeutics, Inc. (VVOS) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on June 25, 2026, covering events occurring between June 5, 2026, and June 22, 2026. The filing details a material amendment to a debt-for-equity exchange agreement with Streeterville Capital, LLC.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, or liquidity figures. The primary financial metric disclosed is a financing milestone requirement of at least $2,600,000.
Material Changes
- Debt Restructuring Extension: On June 18, 2026, the Company entered into a Letter Agreement with Streeterville Capital, LLC to amend the Exchange Agreement originally signed on June 5, 2026.
- Financing Deadline: The "outside date" by which the Company must complete a qualifying financing of at least $2,600,000 was extended from June 15, 2026, to August 31, 2026.
- Transaction Structure: The underlying agreement involves Streeterville exchanging a portion of outstanding indebtedness owed by the Company for shares of the Company's preferred stock and common stock.
Outlook, Risks, and Management Commentary
The Company issued a press release on June 22, 2026, announcing the extension of the financing deadline. The filing indicates that the Company is actively working to secure the required $2,600,000 in qualifying financing to satisfy the terms of the Exchange Agreement. Failure to meet this deadline by August 31, 2026, could result in adverse consequences under the agreement terms, though specific penalties are not detailed in this summary text.
Investor Verification Checklist
- Verify the full terms of the Exchange Agreement (Exhibit 10.1) and the Letter Agreement (Exhibit 10.2) to understand consequences of missing the August 31, 2026, financing deadline.
- Confirm the specific valuation and conversion rates for the debt-to-equity swap.
- Monitor subsequent filings for updates on the status of the $2,600,000 qualifying financing.
- Review the June 22, 2026, press release (Exhibit 99.1) for additional management commentary on the company's liquidity position.